Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs
(Thomson Reuters ONE) -
Novartis International AG /
Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and
Mekinist® in certain NSCLC patients with unmet needs
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* In Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+
NSCLC; comparable overall response in those with or without brain
metastases[1],[2]
* Tafinlar (dabrafenib) and Mekinist (trametinib) combination Phase II data
show 63% overall response rate in patients with metastatic BRAF V600E+
NSCLC[3]
* Novartis leadership in lung cancer continues to grow, with research focused
on precision medicines that treat aggressive NSCLC tumors
Basel, June 1, 2015 - Novartis today announced new data from two Phase II
studies of Zykadia(®) (ceritinib), as well as one Phase II study of Tafinlar(®)
(dabrafenib) in combination with Mekinist(®) (trametinib) in certain patients
with non-small cell lung cancer (NSCLC). Data from these studies were presented
at the 51(st) Annual Meeting of the American Society of Clinical Oncology (ASCO)
in Chicago.
The results of the Zykadia studies - ASCEND-2 and ASCEND-3 - reinforce the
efficacy of the medicine in patients with anaplastic lymphoma kinase-positive
(ALK+) NSCLC who had received previous treatment with an ALK inhibitor and in
those receiving an ALK-targeted therapy for the first time. Overall response
rates (ORR) seen in these trials were 38.6% and 63.7%, respectively, based upon
investigator assessment. Comparable ORR results were observed in patients with
ALK+ NSCLC who entered the studies with brain metastases (33% and 58%,
respectively)[1],[2].
Separately, the study of dabrafenib in combination with trametinib in patients
with metastatic BRAF V600E-mutation positive NSCLC who had failed at least one
round of chemotherapy demonstrated an ORR of 63% in this population[3].
"As our lung cancer portfolio and pipeline continue to mature and grow, we are
impressed by the level of activity these targeted treatments demonstrate in
patients with specific genetic mutations in NSCLC," said Alessandro Riva, MD,
Global Head, Novartis Oncology Development and Medical Affairs. "Our continued
studies of Zykadia and the Tafinlar and Mekinist combination, other targeted
medicines, as well as our partnerships with the oncology community to develop
practice-changing immunotherapy combinations, demonstrate our strong commitment
to patients living with lung cancer."
About the Zykadia trials
ASCEND-2 is a Phase II single-arm, open-label, multicenter study which included
140 adults with ALK+ NSCLC who had been previously treated with chemotherapy and
crizotinib. In addition to the ORR of 38.6% [95% CI: 30.5, 47.2%], patients in
the trial demonstrated a median duration of response (DOR) of 9.7 months [95%
CI: 7.1, 11.1 months] and a median progression-free survival (PFS) of 5.7 months
[95% CI: 5.4, 7.6 months], based on investigator assessment, following treatment
with Zykadia. The most frequent adverse events (incidence >50%) were nausea
(81.4%), diarrhea (80.0%), and vomiting (62.9%)[1].
ASCEND-3 is a Phase II single-arm, open-label, multicenter study which included
124 patients with ALK+ NSCLC who had received up to three lines of chemotherapy
and had no prior experience with an ALK inhibitor. In addition to the ORR of
63.7% [95% CI: 54.6, 72.2%], patients in the trial demonstrated a median DOR of
9.3 months [95% CI: 9.1, not estimable (NE) months] and a median PFS of 11.1
months [95% CI: 9.3, NE months], based on investigator assessment, following
treatment with Zykadia. The most frequent adverse events (incidence >50%) were
diarrhea (82.3%), nausea (74.2%) and vomiting (66.9%)[2]. Use of Zykadia in this
patient population is investigational in the European Union and the United
States.
In ASCEND-2 and ASCEND-3, brain metastases at baseline were seen in 71.4% and
40.3% of patients, respectively. The ORR, DOR and PFS for patients with brain
metastases at baseline were similar with those reported for the overall
population of these studies[1],[2].
"These Phase II results are very useful to clinicians in management of ALK+
NSCLC as they confirm the role of ceritinib in tumors with resistance to
chemotherapy and crizotinib," said Tony S. K. Mok, MD, Professor in Clinical
Oncology at The Chinese University of Hong Kong. "In addition, the comparable
systemic activity seen in ALK+ NSCLC patients with brain metastases is
encouraging, as this is a common and challenging population to manage."
Approximately 2-7% of patients with NSCLC harbor the ALK gene rearrangement,
which causes cancer growth[4]. These patients are candidates for treatment with
a targeted ALK inhibitor. Patients with ALK+ NSCLC are often younger than the
average NSCLC patient, and in many cases have never smoked[5].
About the Tafinlar/Mekinist trial
In the single-arm, two-stage, Phase II trial, patients with metastatic NSCLC who
had the BRAF V600E mutation and failed at least one line of chemotherapy took
150 mg of Tafinlar twice daily and 2 mg of Mekinist once daily. The primary
endpoint of the trial was investigator-assessed ORR. The ORR among 24 patients
evaluable for efficacy was 63% [95% CI: 40.6, 81.2%], with responses being
observed by the first scan (6 weeks), and disease control rate for >12 weeks was
88% [95% CI: 67.6, 97.3%]. Independent review response rates were consistent
with investigator-assessed response. The most common adverse events (incidence
/>20%) among patients included in this analysis were pyrexia, diarrhea, nausea,
vomiting, decreased appetite, asthenia, cough, peripheral edema, and rash[3].
"With no approved therapies for patients with NSCLC who have the BRAF V600E
mutation, the lung cancer community is in dire need of targeted treatments,"
said David Planchard, MD, PhD, Thoracic Oncology Specialist, Cancer Institute
Gustave-Roussy, Villejuif, France. "The initial data from this Phase II study
indicate that combination of dabrafenib and trametinib may hold potential for
this patient population."
Up to 3% of patients with NSCLC have the BRAF V600E mutation, which results in
constitutive signaling, leading to cell proliferation and escape from apoptosis,
or cell death[6].
Tafinlar and Mekinist are being investigated in combination as a potential
treatment for metastatic BRAF V600E-mutation positive NSCLC. Tafinlar and
Mekinist are not approved as monotherapies or in combination anywhere in the
world to treat NSCLC.
Novartis Commitment to Lung Cancer
Novartis research in precision oncology has helped transform treatment
approaches for patients living with genetically-driven types of lung cancer.
Zykadia is one of the first medicines to be approved following FDA Breakthrough
Therapy designation, and was commercially available in the US less than three
and a half years after the first patient entered a clinical trial.
Novartis continues its commitment to the global lung cancer community through
ongoing studies of Zykadia and of Tafinlar and Mekinist in combination, as well
as the exploration of investigational compounds that target genetic biomarkers
in NSCLC beyond ALK and BRAF V600E. EGF816, targeting EGFR, and INC280,
targeting cMET, are currently in Phase I/II clinical trials. Novartis is also
collaborating with Bristol-Myers Squibb to study Zykadia, EGF816 and INC280 in
combination with Bristol-Myers Squibb's immuno-oncology drug, Opdivo
(nivolumab), to gauge whether combining targeted agents with immunotherapy can
increase efficacy in certain lung cancer patients.
About Zykadia
Zykadia is an oral, selective inhibitor of anaplastic lymphoma kinase (ALK), a
gene that can fuse with others to form an abnormal "fusion protein" that
promotes the development and growth of certain tumors in cancers including non-
small cell lung cancer (NSCLC). Zykadia is approved by the European Commission
for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-
positive advanced non-small cell lung cancer (NSCLC) previously treated with
crizotinib. Outside the European Union, Zykadia is approved for patients with
ALK+ NSCLC in the United States and other countries within North America, South
America, Central America and Asia. Additional regulatory reviews for Zykadia are
underway worldwide.
Zykadia Important Safety Information
Zykadia may cause serious side effects.
Zykadia may cause stomach upset and intestinal problems in most patients,
including diarrhea, nausea, vomiting and stomach-area pain. These problems can
be severe. Patients should follow their doctor's instructions about taking
medicines to help these symptoms, and should call their doctor for advice if
symptoms are severe or do not go away.
Zykadia may cause severe liver injury. Patients should have blood tests prior to
the start of treatment with Zykadia, every two weeks for the first month of
treatment and monthly thereafter, and should talk to their doctor right away if
they experience any of the following symptoms: tiredness (fatigue), itchy skin,
yellowing of the skin or the whites of the eyes, nausea or vomiting, decreased
appetite, pain on the right side of the abdomen, urine turns dark or brown, or
bleeding or bruising more easily than normal.
Zykadia may cause severe or life-threatening swelling (inflammation) of the
lungs during treatment that can lead to death. Symptoms may be similar to those
symptoms from lung cancer. Patients should tell their doctor right away about
any new or worsening symptoms, including trouble breathing or shortness of
breath, fever, cough, with or without mucous, or chest pain.
Zykadia may cause very slow, very fast, or abnormal heartbeats. Doctors should
check their patient's heart during treatment with Zykadia. Patients should tell
their doctor right away if they feel new chest pain or discomfort, dizziness or
lightheadedness, faint, or have abnormal heartbeats, blue discoloration of lips,
shortness of breath, swelling of lower limbs or skin, or if they start to take
or have any changes in heart or blood pressure medicines.
Zykadia may cause high levels of glucose in the blood. People who have diabetes
or glucose intolerance, or who take a corticosteroid medicine have an increased
risk of high blood sugar with Zykadia. Patients should have glucose blood tests
prior to the start of treatment with Zykadia and during treatment. Patients
should follow their doctor's instructions about blood sugar monitoring and call
their doctor right away with any symptoms of high blood sugar, including
increased thirst and/or urinating often.
Before patients take Zykadia, they should tell their doctor about all medical
conditions, including liver problems; diabetes or high blood sugar; heart
problems, including a condition called long QT syndrome; if they are pregnant,
if they think they may be pregnant, or if they plan to become pregnant; are
breastfeeding or plan to breastfeed.
Zykadia may harm unborn babies. Women who are able to become pregnant must use a
highly effective method of birth control (contraception) during treatment with
Zykadia and up to 3 months after stopping Zykadia. It is not known if Zykadia
passes into breast milk. Patients and their doctor should decide whether to take
Zykadia or breastfeed, but should not do both.
Patients should tell their doctor about medicines they take, including
prescription medicines, over-the-counter medicines, vitamins and herbal
supplements. If they take Zykadia while using oral contraceptives, the oral
contraceptives may become ineffective.
The most common adverse reactions with an incidence of >=10% were diarrhea,
nausea, vomiting, tiredness (fatigue), liver laboratory test abnormalities
(requires blood test monitoring), abdominal pain, decreased appetite,
constipation, rash, kidney laboratory test abnormalities (requires blood test
monitoring), heartburn and anemia. Grade 3-4 adverse reactions with an incidence
of >=5% were liver laboratory test abnormalities, tiredness (fatigue), diarrhea,
nausea and hyperglycemia (requires blood test monitoring).
Patients should stop taking Zykadia and seek medical help immediately if they
experience any of the following, which may be signs of an allergic reaction:
* Difficulty in breathing or swallowing
* Swelling of the face, lips, tongue or throat
* Severe itching of the skin, with a red rash or raised bumps
Patients should tell their doctor of any side effect that bothers them or does
not go away. These are not all of the possible side effects of Zykadia. For more
information, patients should ask their doctor or pharmacist.
Patients should take Zykadia exactly as their health care provider tells them.
Patients should not change their dose or stop taking Zykadia unless their health
care provider advises them to. Zykadia should be taken once a day on an empty
stomach. Patients should not eat for at least 2 hours before and 2 hours after
taking Zykadia. If a dose of Zykadia is missed, they should take it as soon as
they remember. If their next dose is due within the next 12 hours, they should
skip the missed dose and take the next dose at their regular time. They should
not take a double dose to make up for a forgotten dose. Patients should not
drink grapefruit juice or eat grapefruit during treatment with Zykadia, as it
may make the amount of Zykadia in their blood increase to a harmful level. If
patients have to vomit after swallowing Zykadia capsules, they should not take
more capsules until their next scheduled dose.
Please see full Prescribing Information for Zykadia.
About Tafinlar and Mekinist Combination
Combination use of Tafinlar and Mekinist in patients with unresectable or
metastatic melanoma who have BRAF V600E/K mutation is approved in the US,
Australia, Chile and Canada.
Tafinlar and Mekinist target two different serine/threonine kinases - BRAF and
MEK, respectively - in the RAS/RAF/MEK/ERK pathway, which is implicated in NSCLC
and melanoma, among other cancers. When Mekinist is used with Tafinlar, the
combination has been shown to slow tumor growth more effectively compared with
either drug alone. The combination of Tafinlar and Mekinist is currently being
investigated in an ongoing clinical trial program conducted in study centers
worldwide.
In 2015, Novartis, as successor in interest to GlaxoSmithKline, purchased the
worldwide exclusive rights to develop, manufacture, and commercialize
trametinib, from Japan Tobacco Inc. (JT). JT retains co-promotion rights in
Japan.
Tafinlar and Mekinist are registered trademarks of Novartis Pharma AG or its
affiliates. The safety and efficacy profile of the Tafinlar and Mekinist
combination has not yet been established outside the approved indication.
Tafinlar and Mekinist Combination Important Safety Information
Tafinlar and Mekinist combination may cause serious side effects, such as:
When Tafinlar is used in combination with Mekinist, or when Tafinlar is
administered as monotherapy, it can cause new cancers (both skin cancer and non-
skin cancer). Patients should be advised to contact their doctor immediately for
any new lesions, changes to existing lesions on their skin, or signs and
symptoms of other malignancies.
Before taking Tafinlar in combination with Mekinist, doctors should test their
patients for BRAF wild-type melanoma, as patients without BRAF mutation and with
RAS mutation can be at risk of increased cell proliferation in the presence of a
BRAF inhibitor.
When Tafinlar is used in combination with Mekinist, it can increase the
incidence and severity of bleeding, and in some cases can lead to death.
Patients should be advised to call their healthcare provider and get medical
help right away if they have headaches, dizziness, or feel weak, cough up blood
or blood clots, vomit blood or their vomit looks like "coffee grounds," have red
or black stools that look like tar, or any unusual signs of bleeding.
Tafinlar, in combination with Mekinist, can cause blood clots in the arms or
legs, which can travel to the lungs and can lead to death. Patients should be
advised to get medical help right away if they have the following symptoms:
chest pain, sudden shortness of breath or trouble breathing, pain in their legs
with or without swelling, swelling in their arms or legs, or a cool or pale arm
or leg.
Tafinlar in combination with Mekinist can cause heart problems, including heart
failure. A patient's heart function should be checked before and during
treatment. Patients should be advised to call their healthcare provider right
away if they have any of the following signs and symptoms of a heart problem:
feeling like their heart is pounding or racing, shortness of breath, swelling of
their ankles and feet, or feeling lightheaded.
Tafinlar alone, or in combination with Mekinist, can cause severe eye problems
that can lead to blindness. Patients should be advised to call their healthcare
provider right away if they get these symptoms of eye problems: blurred vision,
loss of vision, or other vision changes, seeing color dots, halo (seeing blurred
outline around objects), eye pain, swelling, or redness.
Patients should notify their doctor if they experience any new or worsening
symptoms of lung or breathing problems, including shortness of breath or cough.
Tafinlar alone or in combination with Mekinist can cause fever which may be
serious. When taking Tafinlar in combination with Mekinist, fever may happen
more often or may be more severe. In some cases, chills or shaking chills, too
much fluid loss (dehydration), low blood pressure, dizziness, or kidney problems
may happen with the fever. Patients should be advised to call their healthcare
provider right away if they get a fever above 38.5(o)C (101.3(o)F) while taking
Tafinlar.
Rash is a common side effect of Tafinlar alone, or when used in combination with
Mekinist. Tafinlar alone, or in combination with Mekinist, can also cause other
skin reactions. In some cases these rashes and other skin reactions can be
severe, and may need to be treated in a hospital. Patients should be advised to
call their healthcare provider if they get any of the following symptoms: skin
rash that bothers them or does not go away, acne, redness, swelling, peeling, or
tenderness of hands or feet, skin redness.
Some people may develop high blood sugar or worsening diabetes during treatment
with Tafinlar, alone or in combination with Mekinist. For patients who are
diabetic, their healthcare provider should check their blood sugar levels
closely during treatment. Their diabetes medicine may need to be changed.
Patients should be advised to tell their healthcare provider if they have any of
the following symptoms of severe high blood sugar: increased thirst or urinating
more often than normal, or urinating an increased amount of urine.
Tafinlar may cause healthy red blood cells to break down too early in people
with G6PD deficiency. This may lead to a type of anemia called hemolytic anemia
where the body does not have enough healthy red blood cells. Patients should be
advised to tell their healthcare provider if they have any of the following
signs or symptoms of anemia or breakdown of red blood cells: yellow skin
(jaundice), weakness or dizziness, or shortness of breath.
Tafinlar and Mekinist both can cause harm to an unborn baby when taken by a
pregnant woman. Tafinlar can also render hormonal contraceptives ineffective.
The most common side effects of Tafinlar and Mekinist combination include fever,
nausea, tiredness, rash, chills, diarrhea, headache, vomiting, hypertension,
joint pain, peripheral edema and cough. The incidence and severity of fever is
increased when Mekinist is used in combination with Tafinlar.
Patients should tell their doctor of any side effect that bothers them or does
not go away. These are not all of the possible side effects of Tafinlar and
Mekinist combination. For more information, patients should ask their doctor or
pharmacist.
Patients should take Tafinlar and Mekinist combination exactly as their health
care provider tells them. Patients should not change their dose or stop taking
Tafinlar and Mekinist combination unless their health care provider advises them
to. Mekinist should be taken only once daily (either in the morning or evening,
at the same time as Tafinlar). The first and second dose of Tafinlar should be
taken approximately 12 hours apart. Patients should take Tafinlar and Mekinist
at least 1 hour before or 2 hours after a meal. Do not take a missed dose of
Tafinlar within 6 hours of the next dose of Tafinlar. Do not open, crush, or
break Tafinlar capsules. Do not take a missed dose of Mekinist within 12 hours
of the next dose of Mekinist.
Please see full Prescribing Information for Tafinlar and Mekinist.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "continues," "focused on," "continue," "continued,"
"commitment," "encouraging," "indicate," "may," "potential," "being
investigated," "ongoing," "exploration," "investigational," "can," "yet," or
similar terms, or by express or implied discussions regarding potential new
indications or labeling for Zykadia, Tafinlar and Mekinist, potential marketing
approvals for EGF816 and INC280, or regarding potential future revenues from
such products and investigational compounds. You should not place undue reliance
on these statements. Such forward-looking statements are based on the current
beliefs and expectations of management regarding future events, and are subject
to significant known and unknown risks and uncertainties. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that Zykadia, Tafinlar or
Mekinist will be submitted or approved for any additional indications or
labeling in any market, or at any particular time. Neither can there be any
guarantee that EGF816 or INC280 will be submitted or approved for sale in any
market, or at any particular time. Nor can there be any guarantee that such
products and investigational compounds will be commercially successful in the
future. In particular, management's expectations regarding such products and
investigational compounds could be affected by, among other things, the
uncertainties inherent in research and development, including unexpected
clinical trial results and additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally; the
company's ability to obtain or maintain proprietary intellectual property
protection; general economic and industry conditions; global trends toward
health care cost containment, including ongoing pricing pressures; unexpected
manufacturing issues, and other risks and factors referred to in Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date and
does not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events or
otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2014, the Group achieved net
sales of USD 58.0 billion, while R&D throughout the Group amounted to
approximately USD 9.9 billion (USD 9.6 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 120,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
References
[1] Mok, T. et al. ASCEND-2: a single-arm, open-label, multicenter Phase 2
study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-
small cell lung cancer (NSCLC) previously treated with chemotherapy and
crizotinib (CRZ). Abstract #8059. 2015 American Society of Clinical
Oncology (ASCO) Annual Meeting, Chicago, IL, USA.
[2] Felip, E. et al. ASCEND-3: a single-arm, open-label, multicenter Phase 2
study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged
(ALK+) non-small cell lung cancer (NSCLC). Abstract #8060. 2015 American
Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA.
[3] Planchard, D. et al. Interim results of a phase 2 study of the BRAF
inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor
trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic
non-small cell lung cancer (NSCLC). Abstract #8006. 2015 American Society
of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA.
[4] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice
Guidelines in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer. NCCN
2014 3:1-148.
[5] Shaw A, et al. Targeting Anaplastic Lymphoma Kinase in Lung Cancer. Clin
Cancer Res 2011;17:2081-2086.
[6] Chen D. et al. BRAF Mutations in Patients with Non-Small Cell Lung Cancer:
A Systematic Review and Meta-Analysis. PLOS One 2014; 9:6, 1-7.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Nicole Riley
Novartis Global Media Relations Novartis Oncology
+41 61 324 7999 (direct) +1 862 778 3110 (direct)
+41 79 593 4202 (mobile) +1 862 926 9040 (mobile)
eric.althoff(at)novartis.com nicole.riley(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448
Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1925292/690767.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1925292]
Unternehmensinformation / Kurzprofil:
Datum: 01.06.2015 - 15:00 Uhr
Sprache: Deutsch
News-ID 397204
Anzahl Zeichen: 31196
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 130 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
